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OBJECTIVE: The protocols for glucocorticoid replacement in children with salt wasting 21-hydroxylase
deficiency are well established; however, the current recommendation for mineralocorticoid replacement is
general and suggests individualized dose adjustments. This study aims to retrospectively review the 9-/-
fludrocortisone dose regimen in salt wasting 21-hydroxylase deficient children who have been adequately
treated during infancy.
METHODS: Twenty-three salt wasting 21-hydroxylase deficient patients with good anthropometric and
hormonal control were followed in our center since diagnosis. The assessments of cortisone acetate and 9-/-
fludrocortisone doses, anthropometric parameters, and biochemical and hormonal levels were rigorously
evaluated in pre-determined intervals from diagnosis to two years of age.
RESULTS: The 9-/-fludrocortisone doses decreased over time during the first and second years of life; the
median fludrocortisone doses were 200 mg at 0-6 months, 150 mg at 7-18 months and 125 mg at 19-24 months.
The cortisone acetate dose per square meter was stable during follow-up (median=16.8 mg/m2/day). The serum
sodium, potassium and plasma rennin activity levels during treatment were normal, except in the first month of
life, when periodic 9-/-fludrocortisone dose adjustments were made.
CONCLUSIONS: The mineralocorticoid needs of salt wasting 21-hydroxylase deficient patients are greater
during early infancy and progressively decrease during the first two years of life, which confirms that a partial
aldosterone resistance exists during this time. Our study proposes a safety regiment for mineralocorticoid
replacement during this critical developmental period.
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& INTRODUCTION
Congenital adrenal hyperplasia due to 21-hydroxylase
deficiency (21OHD) is a common genetic disorder that
accounts for .90% of congenital adrenal hyperplasia cases.
Mutations in the CYP21A2 gene, which encodes 21-hydro-
xylase (an enzyme involved in aldosterone and cortisol
biosynthesis), cause 21OHD. ACTH levels rise because of
impaired cortisol secretions, thereby stimulating the adrenal
cortex and accumulating androgen precursors, whichmanifest
in varying degrees of hyperandrogenism. The severity of
clinical symptoms and hormonal abnormalities correlates with
the severity of enzymatic impairment manifested through
three main phenotypes: the non-classical form, the classical
simple virilizing form and the classical salt wasting (SW) form,
which is the most severe (1, 2).
In SW-21OHD, patients display CYP21A2 mutations that
abolish 21-hydroxylase activity and completely disrupt the
cortisol and aldosterone biosynthesis. Females present with
virilized external genitalia at birth, and both sexes present
with adrenal crisis in the first months of life. This adrenal
crisis is characterized by hyponatremia, hyperkalemia,
hyperreninemia and dehydration and leads to acute
circulatory collapse if left untreated (2). SW-21OHD treat-
ment consists of glucocorticoid and mineralocorticoid
replacement in conjunction with sodium chloride supple-
mentation during infancy (3).
The guidelines for glucocorticoid replacement in children
are well established (3) and include short half-life gluco-
corticoids to prevent adrenal crises and virilization, along
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with minimizing the growth suppression associated with
longer-acting glucocorticoids (4). The current recommenda-
tion for mineralocorticoid replacement in SW-21OHD is
based on expert opinions that suggest an initial dose of 100-
200 mg/day of 9-a-fludrocortisone, regular dose reassess-
ment and individualized adjustments (3). The dose adjust-
ments should be based on clinical and laboratory
parameters, such as blood pressure, sodium, potassium
and plasmatic renin activity (PRA) levels (5).
Mineralocorticoid replacement doses vary during infancy
primarily because of improvements in mineralocorticoid
sensitivity, which tends to increase, particularly during the
first year of life (6). The higher mineralocorticoid demand
during early infancy is explained by renal function
immaturity, the limited sodium content in human breast
milk and higher sodium requirements for child develop-
ment during this period (7, 8).
Despite the importance of mineralocorticoid treatment
during infancy in SW-21OHD patients, there is a lack of data
in the literature concerning the optimal replacement dosage.
The only study that has evaluated 9-a-fludrocortisone
replacement doses was the European-wide survey, which
included 125 centers that were actively involved in caring
for 21OHD patients. The questionnaire results showed a
wide range for 9-a-fludrocortisone doses and divided
opinions concerning the need for sodium supplementation
(9).
To improve mineralocorticoid management during this
critical period, we conducted a retrospective analysis of 9-/-
fludrocortisone replacement doses and the clinical and
laboratory follow-up parameters during the first and second
years of life in our cohort of adequately treated SW-21OHD
patients.
& PATIENTS AND METHODS
The study protocol was approved by the Institutional
Review Board, and informed consent was obtained from all
of the patients or their parents. Our cases were selected from
a large cohort of 141 SW-21OHD patients who were
followed at the Endocrinology Division in our center. The
inclusion criteria were regular follow-up in our institution
from diagnosis or early age (maximum 90 days) to two years
of age and adequate clinical and hormonal control. Our
cohort comprised 23 SW-21OHD patients who were homo-
geneously treated and assisted by the same physicians from
1988 to 2006.
The females had ambiguous genitalia and dehydration
with hyponatremia and/or hyperkalemia at diagnosis,
while the males were diagnosed based on dehydration with
hyponatremia and hyperkalemia or the previous knowledge
of an older affected sibling. At the diagnosis, all of the
patients had high basal levels of 17-hydroxyprogesterone
(17OHP) (.50 ng/mL), and the PRA (when available) was
usually .20 ng/mL/h. The SW-21OHD diagnosis was
confirmed by identification of homozygous or compound
heterozygous CYP21A2 mutations, which predicted total or
near total impairment of enzymatic activity (Table 1) (10).
The patients were initially treated with cortisone acetate:
,18 mg/m2/day divided into three doses and 9-a-fludro-
cortisone 100-200 mg/day. Two grams/day of sodium
chloride was supplemented during exclusive breastfeeding
periods. The patients were evaluated weekly during the first
two months of life, monthly from three to six months of life
and every three months thereafter. Clinical data, such as
height, weight, blood pressure and sodium and potassium
levels, were measured at every appointment. Basal serum
testosterone, androstenedione, 17OHP and PRA levels were
Table 1 - Clinical basal hormone levels and molecular data of the SW-21OHD infants.
Case Age at Clinical 17OHP Testo Andro Na/K PRA CYP21A2
Diagnosis (days) Karyotype Manifestations (ng/ml) (ng/dl) (ng/ml) (mEq/L) ng/mL/h Genotype
1* 7 XY NBS 626 - - 129/7.9 21 Del8/Cluster
2* 1 XY NBS/AS 539 1,500 - 125/8.4 .25 Del8/Cluster
3 1 XX NBS/AG 240 .1,500 - 134/6.2 8.7 I2/I2
4 2 XX AG 232 - - 133/5.7 - I2/I2
5 91 XX AG/D 236 177** 9.6 117/8.0 32 Conv/I2
6 30 XX AG/D 656 289** 14.9 114/8.6 24.5 I2/Ins A
7 16 XX AG/D 145 1,500 .10 131/6.4 .25 -
8 12 XX AG/D 156 137 27 131/7.5 .30 I2/I2
9 18 XX AG/D 338 125** - 133/6.4 .30 I2/I2
10* 6 XY D/AS 134 1,260 .8.5 132/7.6 - Q318X/I2
11* 16 XX AG/D 200 - - 118/6.7 .25 Q318X/I2
12 15 XX AG/D 194 - - 127/9.0 19 Conv/Conv
13 60 XX AG/D 217 75 4.7 125/6.6 .25 Conv/I2
14 At birth XY AS 192 840 8.1 136/5.5 .22 Conv/I2
15 6 XY D/AS 110 746 .10 133/5.6 .37 Q318X/R356W
16 23 XX AG/D 168 118** 18.3 110/8.0 - I2/H365Y
17 24 XX AG/D 59 910** - 120/5.3 .19.6 I2/IVS2+5 G.A
18 20 XX AG/D 76 - - 130.5.2 - I2/Q318X
+R356W
19 30 XY D 160 - - 110/11.6 - Del 8/Del 8
20 5 XX AG 95 772 - 135/3.5 - I2/I2
21 30 XX AG/D .20 350 .10 22.3 Q318X/I2
22 60 XY D .20 200 14 107/6.5 .25 -
23 39 XY D/AS 132 244 - 110/8.4 .25 E351V/I2
NBS: Newborn screening; AG: ambiguous genitalia; D: dehydration; AS: affected sibling; Andro: androstenedione; Testo: testosterone; Del: deletion, I2:
intron two splice, Ins: insertion; Conv: Conversion; - : data not available; *: Sibling; ** Radioimmunoassay;
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measured every three months. Mineralocorticoid treatment
was considered adequate if the sodium and potassium
levels were maintained within the normal or near normal
range and if the PRA levels were within the upper limit of
the normal range. Glucocorticoid treatment did not attempt
to normalize the 17OHP levels and was considered
adequate if at least three of the four assessments (per year)
of testosterone and androstenedione levels were also
normal.
During the first two years of life, the cortisone acetate and
9-a-fludrocortisone doses and clinical and laboratory data,
such as height, weight, blood pressure, sodium levels,
potassium levels and PRA levels, were reviewed in our
cohort.
Hormonal assays and genetic analysis
Radioimmunoassay of 17OHP was measured using com-
mercial reagents (Diagnostic Systems Laboratories Inc.,
Webster, TX, USA); the intra-assay and inter-assay coeffi-
cients of variation were ,9%. The PRA was measured by
radioimmunoassay using commercial reagents (Diasorin,
Stillwater, MN, USA); the intra-assay and inter-assay
coefficients of variation were ,8% and ,7%, respectively.
From 1992 to 1997, testosterone was measured with radio-
immunoassay (Diagnostic Systems Laboratories Inc.,
Webster, TX, USA), and the intra-assay and inter-assay
coefficients of variation were ,10-12%. After 1997, testoster-
one was measured with fluoroimmunoassay (AutoDELFIA,
Perkin Elmer Inc., Walthan, MA, USA); the intra-assay and
inter-assay coefficients of variation were ,3% and ,6%,
respectively. Androstenedione was measured with radio-
immunoassay (Diagnostic Systems Laboratories Inc.,
Webster, TX, USA). The intra-assay and inter-assay coeffi-
cients were ,10%.
The genetic analyses of CYP21A2 included Southern
blotting, followed by hybridization with a genomic CYP21
probe to investigate large rearrangements (11) and allele-
specific PCR to investigate 15 common micro-conversions
(10). Direct sequencing was performed when the mutations
were not detected in both of the alleles or were not
concordant with the phenotype (12).
Statistics
The results are presented as the median, mean and SD.
The group comparisons were performed with a Kruskal-
Wallis one-way analysis of variance on rank, followed by
Dunn’s post test; p,0.05 was considered significant. The
graphics were designed using Prism 3 software (GraphPad
Software Inc., San Diego, CA, USA).
& RESULTS
In the 23 salt wasting 21OHD patients studied, the salt
wasting crises occurred at a mean age of 23 days (range 6-90
days). The mean basal sodium level at the time of diagnosis
was 128 mEq/L (range 107-136 mEq/L), and the mean
potassium level was 6.7 mEq/L (range 4.5-11.6 mEq/L)
(Table 1).
The patients were initially treated with the standard dose
of cortisone acetate (18 mg/m2/day), 9-a-fludrocortisone
(100-200 mg/day) and sodium chloride (2 g/day); the
cortisone acetate and 9-a-fludrocortisone doses were
adjusted according to the above-mentioned clinical and
laboratory parameters.
During follow-up, the need for 9-a-fludrocortisone replace-
ment progressively decreased. The 9-a-fludrocortisone dose
in the first semester of life was significantly higher than in the
second semester, which in turn was significantly higher than
in the second year of life (p,0.01) (Figure 1A). The median 9-
a-fludrocortisone dose from 0-6 months of life was 200 mg/
day (range 100-350 mg), 150 mg/day (range 100-200 mg) from
7-12 months, 150 mg/day (range 50-200 mg) from 13-18
months and 125 mg/day (range 50-200 mg) from 19-24 months
(Figure 1A). Note that the range of 9-a-fludrocortisone doses
during the first six months of life was larger than the range
observed for the following periods (Figure 1A).
In contrast, the cortisone acetate dose (adjusted for body
surface area) was constant during the first two years of life
(mean dose 16.3 mg/m2, SD¡3.4) (Figure 1B).
The mineralocorticoid replacement was adequate in these
patients, as shown by the normal or near normal serum
sodium and potassium levels from the second month to the
second year of life (Figures 2A and 2B). Additionally, PRA
was maintained in the upper limit of the normal range from
three months of age onwards (Figure 3). During the studied
period, none of the patients presented with clinical signs of
mineralocorticoid overload, such as arterial hypertension,
Figure 1 - A) Box plots describe fludrocortisone dose variability
(mg/day) according to age; the dose decreases progressively
during the first 2 years of treatment. B) Box plots describe the
cortisone acetate dose (mg/m2/day) variability. Cortisone acetate
doses per square meter were stable during the first two years of
treatment. The boxes at the lower and upper ends represent the
lower and upper quartiles, respectively, and the bold horizontal
line inside the boxes represents the median dose. The vertical
bars reach from the boxes to the non-outlier minimum and
maximum values.
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tachycardia or congestive heart failure, or deficiencies (e.g.,
dehydration and/or arterial hypotension).
The patients reached normal height (¡1 SD) and weight
(¡1 SD) after two years of treatment, which assured
adequate hormonal replacement. In males, the mean height
and weight were 85.8 cm (SD=0) and 12.6 kg (SD= 0),
respectively; in females, the mean height and weight were
81.3 cm (SD= -1) and 11.7 kg (SD= -0.4), respectively.
& DISCUSSION
Appropriate glucocorticoid and mineralocorticoid replace-
ment during infancy in SW-21OHD children is critical for
maintaining a positive sodium balance that enables adequate
body growth and brain development. Studies evaluating the
late effect of neonatal sodium deficiency in neurological
performance, such as motor function, intelligence (IQ),
memory, language and behavior, have shown poor neurode-
velopment outcomes in the second decade of life (13). Impaired
cognitive function has been observed in 21OHD patients,
particularly with SW-21OHD (14), which reflects the adverse
effects of hyponatremia episodes and suboptimal hormone
replacement therapy. However, the acute consequences of
mineralocorticoid excess are volume overload and congestive
heart failure, and the chronic consequences include growth
impairment caused by its glucocorticoid properties (15).
Therefore, the goal of therapy in SW-21OHD patients is to
normalize the androgen levels and total-body sodium
depletion to allow normal growth and development and
avoid volume overload (16). In our study, the required
glucocorticoid dose (adjusted per square meter) was stable
during the first two years of life. In contrast, the need for 9-
a-fludrocortisone was higher during the first six months
and continually decreased during follow-up; at two years of
age, the mean dose of 9-a-fludrocortisone was 25-35% lower
than the initial dose, which suggested an improvement in
the kidney regulation of salt and water balance.
In fact, a relative state of aldosterone resistance has been
found in the neonatal period (6). Healthy term neonates
exhibit extremely high plasma aldosterone levels (6, 17),
which is most likely an adaptive response to kidney tubular
immaturity at birth (6, 7, 17-19). It has been proposed that
during early infancy, renal proximal tubular cells, which are
responsible for the reabsorption of 60-80% of the filtered
load of salt and water, N+/K+-ATPase (the main enzyme
responsible for active sodium transport), and the miner-
alocorticoid nuclear receptor (MR, the rate-limiting step for
sodium balance in the distal renal tubules) do not reach full
maturation (7). Additionally, in 21OHD patients, the
accumulated androgen precursors, progesterone and
17OH-progesterone (17OHP) inhibit mineralocorticoid
receptor transactivation by aldosterone (20).
The limited sodium content in breast milk most likely also
corresponds with greater 9-a-fludrocortisone requirements in
the first semester of life. The sodium composition of breast
milk ranges from 3-18 mEq/L, and the milk volume produc-
tion is ,800 mL/day, which provides sufficient sodium to
supply a healthy full-term newborn (i.e., ,1-2 mEq/kg/day)
but not enough to replace the sodium deficit that arises in salt
wasting newborns (i.e., ,4-5 mEq/kg/day) (21-23).
The range of mineralocorticoid doses was wider in the
first semester of life, most likely because of the greater inter-
individual variability of mineralocorticoid sensitivity and/
or greater difficulty in setting up an initial mineralocorticoid
dose. Therefore, individual drug adjustments during this
period should be assessed weekly rather than monthly.
In conclusion, this retrospective analysis of 9-a-fludro-
cortisone dose schedules in a group of 21OHD children
during the first two years of life suggests a 9-a-fludrocorti-
sone-dose regimen that closely monitors the anthropo-
metric, clinical and biochemical parameters to ensure
adequate levels and avoid complications related to miner-
alocorticoid under- or overtreatment.
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Figure 2 - A) Box plots show the serum sodium levels in the basal
state, monthly during the first 6 month of life and then every
three months during the first two years of treatment. B) Box
plots show the serum potassium levels in the basal state, monthly
during the first six month of life and then every three months
during the first two years of treatment.
Figure 3 - Box plots show the PRA levels in the basal state and
every three months during the first two years of treatment.
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